Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 14/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656205 | 0.81 | ENPP1 (0.75) | ENPP1KIT | |
| SCHEMBL25656203 | 0.80 | ENPP1 (0.48) | ENPP1KITPIK3CDPIK3CAPIK3CB | |
| SCHEMBL31531464 | 0.72 | ENPP1 (0.75) | ENPP1KITPIK3CDPIK3CAPIK3CB | |
| SCHEMBL25656209 | 0.72 | ENPP1 (0.76) | ENPP1KIT | |
| SCHEMBL23762250 | 0.70 | ENPP1 (0.81) | ENPP1KITCA12CA1CA2 | |
| SCHEMBL25656212 | 0.70 | PIK3CD (0.38) | ENPP1KITPIK3CDPIK3CAPIK3CB | |
| SCHEMBL25656213 | 0.70 | PIK3CD (0.38) | ENPP1KITPIK3CDPIK3CAPIK3CB | |
| SCHEMBL25656204 | 0.70 | TNF (0.41) | ENPP1KITPIK3CDPIK3CAPIK3CB | |
| SCHEMBL25656202 | 0.68 | ENPP1 (0.56) | ENPP1KITCA12CA1CA2 | |
| SCHEMBL25656211 | 0.68 | ENPP1 (0.54) | ENPP1KITPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885KIT 4739/4885CA12 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.